Arena's pain drug fails phase 2b, prompting review of 'strategic options'

A phase 2b clinical trial of Arena Pharmaceuticals’ olorinab has missed its primary endpoint. The cannabinoid receptor 2 agonist failed to reduce abdominal pain in the overall population of irritable bowel syndrome (IBS) patients, but Arena pointed to a subgroup analysis as evidence of efficacy.